Home | Products | News | Contact Us
   

Nutraceutical News

Australia rethinks nutrient labelling and health claims standards
EFSA approves new vitamins and minerals for foods and supplements
Children positive on organic, free-range and hormone-free
Calcium sales growth suffering from lack of novelty
West follow East's functional lead?
Women Looking For An Alternative To Black Cohosh






 

Theobromine Clinical Study


Pentoxifylline affects cytokine reaction in cardiopulmonary bypass.

Iskesen I, Saribulbul O, Cerrahoglu M, Onur E, Destan B, Sirin BH.

Department of Cardiovascular Surgery, Celal Bayar University School of Medicine, Manisa, Turkey. iskesen@yahoo.com

BACKGROUND: Cardiac surgery is associated with an inflammatory response that may cause myocardial dysfunction after cardiopulmonary bypass. We examined the efficacy of pentoxifylline to attenuate the cardiopulmonary bypass-induced inflammatory response during heart operations. METHODS: In a prospective, randomized study, 30 patients undergoing coronary artery bypass graft surgery received either pentoxifylline (group P, n = 15) (continuous infusion of 1.5 mg/kg per hour during operation) or not (group C [control], n = 15). Blood samples for measurements of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-8, and IL-10 were taken from the arterial line in both groups at 5 different time points. RESULTS: TNF-alpha, IL-6, and IL-8 plasma levels increased in both groups after cardiopulmonary bypass, with a higher increase in the control group (P < .05). CONCLUSIONS: Our results indicate that pentoxifylline infusion during cardiac surgery inhibits the proinflammatory cytokine release caused by cardiopulmonary bypass.

PMID: 17060046 [PubMed - indexed for MEDLINE]


<< Back to All Natural Products List

© Copyright 2007 - Nutraceutical Ingredients - All Rights Reservec